Developing novel dual-specific proteins that target multiple receptors for applications in prostate cancer imaging and therapy

Angiogenesis is the process of new blood vessel development, a hallmark of cancer and Prostate Specific Membrane Antigen (PSMA) is a protein expressed on the surface of prostate tumor cells. Dr. Papo intends to produce engineered proteins that will simultaneously bind to PSMA on prostate cancer cells and inhibit angiogenesis. This engineered protein inhibitor should be a drug candidate for the treatment advanced, metastatic prostate cancer.